With this in mind, combinatorial therapy with CTPI-2 and SLC13A5 inhibitors (e.g., gluconate [29]) is likely to be more effective than treatment with either agent alone in NAFLD/NASH. This evidence concerns the gene SLC13A5 and metabolic dysfunction-associated steatotic liver disease.